Phathom Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Phathom Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Phathom Pharmaceuticals Inc recorded a cumulative net loss of $-99 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -35.06%.

However, within the Healthcare sector 454 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4019, from total ROA ranking in the first quarter of 2026 at 4897.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	30.71 %	3.71 %	-31.5 %	-38.27 %	-21.65 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-99	-157	-221	-275	-330
Return On Assets (TTM)	-35.06 %	-59.73 %	-84.89 %	-94.54 %	-100.83 %
PHAT's Total Ranking	# 4019	# 4897	# 4363	# 4457	# 4525
Total Assets (TTM) in million	327	305	259	239	250
Seq. Total Assets Change	7.2 %	17.74 %	8.46 %	-4.51 %	-14.95 %
Seq. Net Income Change	-	-	-	-	-

PHAT's 5 Years Annual ROA >> Back to PHAT Management Effectiveness >> Compare PHAT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 178
Sector	# 455
Overall	# 3692

Return On Assets Statistics
High	Average	Low
-35.02 %	-84.88 %	-182.16 %
(Jun 30 2026)		(Mar 31 2020)

Financial Statements
Phathom Pharmaceuticals Inc 's Assets	$ 327 million	PHAT's Balance sheet
Phathom Pharmaceuticals Inc 's Income	$ -18 million	Quarterly PHAT's Income Statement
PHAT's Income by Division		See PHAT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-31.5 %	-8.3 %	153.55 %	-13.99 %	-35.73 %
Total Assets in million	259	378	413	163	189
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-221	-334	-202	-198	-144
Annual Return On Assets	-85.37 %	-88.37 %	-48.86 %	-121.51 %	-76.06 %

PHAT's 5 Years Annual ROA >> Back to PHAT Management Effectiveness >> Compare PHAT ROA to its Competitors

More Return On Assets Ratios
PHAT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PHAT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PHAT's Competitors
Subscribers only: Roa for Phathom Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for PHAT's Customers

You may also want to know
PHAT's Roi	PHAT's Inventory Turnover Ratio	PHAT's Growth Rates	PHAT's Dividend Comparisons
	PHAT's Profitability Ratios	PHAT's Asset Turnover Ratio	PHAT's Dividend Growth
PHAT's Roe	PHAT's Valuation Ratios	PHAT's Financial Strength Ratios	PHAT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-14T03:59:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.